BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2669133)

  • 1. The management of patients with adenocarcinoma and poorly differentiated carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1989 Aug; 16(4 Suppl 6):116-22. PubMed ID: 2669133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poorly differentiated carcinoma or adenocarcinoma of unknown primary site: long-term results with cisplatin-based chemotherapy.
    Greco FA; Hainsworth JD
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):77-82. PubMed ID: 7992071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary tumor site.
    Hainsworth JD; Greco FA
    Semin Oncol; 1993 Jun; 20(3):279-86. PubMed ID: 8503024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poorly differentiated carcinoma and germ cell tumors.
    Hainsworth JD; Greco FA
    Hematol Oncol Clin North Am; 1991 Dec; 5(6):1223-31. PubMed ID: 1663941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic adeno or undifferentiated carcinoma from an unknown primary site--natural history and guidelines for identification of treatable subsets.
    Kirsten F; Chi CH; Leary JA; Ng AB; Hedley DW; Tattersall MH
    Q J Med; 1987 Feb; 62(238):143-61. PubMed ID: 3659256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Metastatic carcinoma of unknown origin].
    Fizazi K; Culine S
    Bull Cancer; 1998 Jul; 85(7):609-17. PubMed ID: 9752267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.
    Hainsworth JD; Johnson DH; Greco FA
    J Clin Oncol; 1992 Jun; 10(6):912-22. PubMed ID: 1375284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carcinoma of unknown primary site.
    Greco FA; Burris HA; Erland JB; Gray JR; Kalman LA; Schreeder MT; Hainsworth JD
    Cancer; 2000 Dec; 89(12):2655-60. PubMed ID: 11135228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-101-S19-105. PubMed ID: 9427278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing carcinomas of unknown primary site.
    Hainsworth JD; Greco FA
    Oncology (Williston Park); 1988 Jul; 2(7):43-9, 52-4. PubMed ID: 3275052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroendocrine carcinoma of unknown primary site.
    Spigel DR; Hainsworth JD; Greco FA
    Semin Oncol; 2009 Feb; 36(1):52-9. PubMed ID: 19179188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Unknown primary cancer].
    Furue H
    Gan To Kagaku Ryoho; 1998 Jan; 25(1):1-6. PubMed ID: 9464322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary site.
    Hainsworth JD; Dial TW; Greco FA
    Am J Clin Oncol; 1988 Apr; 11(2):138-45. PubMed ID: 2451881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolving role of paclitaxel for patients with carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):129-33. PubMed ID: 10190795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of patients with cancer of unknown primary site.
    Hainsworth JD; Greco FA
    Important Adv Oncol; 1991; ():173-90. PubMed ID: 1869276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poorly differentiated carcinoma of unknown primary site: clinical usefulness of immunoperoxidase staining.
    Hainsworth JD; Wright EP; Johnson DH; Davis BW; Greco FA
    J Clin Oncol; 1991 Nov; 9(11):1931-8. PubMed ID: 1941051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etoposide/cisplatin-based chemotherapy for patients with metastatic poorly differentiated carcinoma of unknown primary site.
    Greco FA; Johnson DH; Hainsworth JD
    Semin Oncol; 1992 Dec; 19(6 Suppl 13):14-8. PubMed ID: 1492223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
    Hainsworth JD; Spigel DR; Litchy S; Greco FA
    J Clin Oncol; 2006 Aug; 24(22):3548-54. PubMed ID: 16877720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cardiac metastasis of poorly differentiated adenocarcinoma of unknown primary site].
    Mazzoccoli G; Carughi S; La Viola M; De Cata A; Puzzolante F; Camagna A; Russo A; Caparrotti S
    Ital Heart J Suppl; 2002 Nov; 3(11):1112-6. PubMed ID: 12506513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast.
    Botti C; Vici P; Lopez M; Scinto AF; Cognetti F; Cavaliere R
    J Am Coll Surg; 1995 Sep; 181(3):202-8. PubMed ID: 7670678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.